A SELECTIVE AND SENSITIVE LC-MS/MS METHOD FOR QUANTIFICATION OF FOUR POTENTIAL GENOTOXIC IMPURITIES IN ATAZANAVIR SULFATE DRUG SUBSTANCE IN TRACE LEVEL

  • SIVA JYOTHI N. Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University) Rudram, Hyderabad, Telangana, India
  • VENKATNARAYANA MUVVALA Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University) Rudram, Hyderabad, Telangana, India

Abstract

Objective: The main objective of current research work is to develop and validate a rapid, sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the trace analysis of four potential genotoxic impurities in Atazanavir Sulfate drug substance.


Methods: LC-MS/MS analysis of four potential genotoxic impurities was done on Acquity UPLC CSH C18 (100 mm × 2.1 mm, 1.7 μm) column. In this method, mobile phase A (10 mM ammonium acetate) mobile phase B (methanol: acetonitrile (90:10, v/v) with gradient run with the flow rate of 0.2 ml/min. The method was developed with the short run time of 13 min. Triple quadrupole mass detector coupled with positive electrospray ionization was used for the quantification of genotoxic impurities in multiple reaction monitoring (MRM) mode.


Results: The method was linear in the range of 0.3 ppm to 4.5 ppm for BOC Hydrazine Acid impurity, BOC Epoxide and Keto impurity with a correlation coefficient not less than 0.9994. The accuracy of the method was in the range of 99.26% to 105.71% for all four potential genotoxic impurities (PGIs). No impurities were identified in the Atazanavir Sulfate active pharmaceutical ingredient sample.


Conclusion: The proposed method is specific, linear, precise, accurate, robust and stable for the quantification of the four genotoxic impurities at very low levels.

Keywords: Atazanavir Sulfate, Genotoxic Impurities, LC-MS/MS, Multiple Reaction monitoring (MRM), Method Development and Validation

References

1. Drug bank online. Atazanavir drug substance. Available from: https://www.drugbank.ca/drugs/DB01072. [Last accessed on 15 Dec 2020].
2. Atazanavir drug information available in NCI Thesaurus (NCIt), with drug code Atazanavir (Code C66872); 2021.
3. Anti-HIV drugs information, PubMed and National Center for Biotechnology Information (NCBI); Atazanavir. Available from: https://www.ncbi.nlm.nih.gov/mesh/2009983. [Last accessed on 15 Dec 2020]
4. Atazanavir sulfate with the brand name; Uses dosage, side effects. Available from: https://www.rxlist.com/reyataz-drug.htm [Last accessed on 15 Dec 2020]
5. Deductive Estimation of Risk from Existing Knowledge (DEREK) nexus, marketed by LHASA Ltd, Leeds, Yorkshire UK, DEREK Version Derek: 3.0.1; Nexus; 2019.
6. FDA, Draft Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches, CDER, Silver Spring, MD, USA; 2008.
7. International Conference on Harmonization Q3A-Q3D: Impurities-International Council for Harmonization guidelines; 2006. p. 1-11.
8. Vijaya Bhaskar Reddy A, Jaafar J, Umar K, Abdul Majid Z, Azmi Bin A, Talib J, et al. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review. J Sep Sci 2015;38:764–79.
9. Lee H. Pharmaceutical industry practices on genotoxic impurities, CRC Press: Boca Raton, FL USA; 2014.
10. European Directorate for the Quality of Medicines and HealthCare (EDQM), the European Pharmacopeia, EDQM, Strasbourg, France. 9th edition; 2017.
11. ICH, “M7 (R1): assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk,” In Proceedings of the International Conference on Harmonisation (ICH), Geneva, Switzerland; 2017.
12. McGovern T, Jacobson Kram D. Regulation of genotoxic and carcinogenic impurities in drug substances and products. Trends Anal Chem 2006;25:790-5.
13. Muller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels. Nationale for determining, testing, and controlling specific impurities in pharmaceuticals that posses potential for genotoxicity, reg. Toxicol Pharmacol 2006;44:198-11.
14. Raman NVVSS, Prasad AVVS, Reddy KV. Strategies for the identification, control, and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective. J Pharm Biomed 2011;55:662–7.
15. Hsieh Y, A Korfmacher W. Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening. Curr Drug Metab 2006;7:479–80.
16. Lee MS, Kerns EH. LC/MS applications in drug development. Mass Spectrom Rev 1999;18:187–9.
17. Chitttturi SR, Somannavar YS, Peruri BG, Nallapati S, Sharma HK, Budider SR, et al. Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulphate. J Pharm Biomed Anal 2011;55:31-7.
18. Bhirud CH, Hiremath SN. Stability indicating RP-HPLC method for the determination of atazanavir sulphate in bulk and dosage form. Drug Invent Today 2013;5:81-6.
19. Dey S, Subhasis Patro S, Suresh Babu N, Murthy PN. Development and validation of a stability-indicating RP–HPLC method for estimation of Atazanavir sulfate in bulk. J Pharm Anal 2013;12:1-2.
20. Devi PR, Mukkanti K, Srinivasarao K. Simultaneous estimation of atazanavir sulfate and ritonavir by RP-HPLC method in combined tablet dosage forms and it?s in vitro dissolution assessment Novus. Int J Anal 2012;1:5-14.
21. Srinivasu K, Rao JV, Raju NA. A validated RP-HPLC method for the determination of atazanavir in pharmaceutical dosage form. E J Chem 2011;8:453-6.
22. Dey S, Reddy YV, Reddy T. Method development and validation for the estimation of atazanavir in bulk and pharmaceutical dosage forms and its stress degradation studies using UV–VIS spectrophotometric method. Int J Pharm Bio Sci 2010;1:1-12.
23. Mastanamma SK, Kumar A, Srivani G, Sridhar T, Sankar Naik B, Kumar V. Stability indicating validated reverse phase-high performance liquid chromatography method for simultaneous determination of Cobicistat and Atazanavir sulfate in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res 2016;9:62-70.
24. Subbaiah N, Subba reddy GV. Method development and validation by LC-MS for trace level quantification of BOC epoxide in atazanavir sulphate. Int J Pharm Pharm Sci 2017;9:143-8.
25. Geeta Bhavani K, Srinivasu N. Determination of genotoxic impurity in atazanavir sulphate substance by LC-MS, J Pharm Biomed Anal 2017;132:156-8.
26. Guideline for Validation of Analytical Procedures, Q2(R1), ICH; 2003.
27. The International Conference on Harmonization, Q1 (A) R2, Stability testing of new drug substances, Current step 4 versions; 2003.
28. United States Pharmacopeia 28-NF 23. The United States Pharmacopoeial Convention Inc. Rockville, MD; 2005. p. 748.
29. Narasimha Rao L, Devanna N, Suresh Reddy KVN. Method development and validation study for the quantitative determination of genotoxic impurity and its precursor in fluconazole sample by liquid chromatography-tandem mass spectroscopy. Int J Pharm Pharm Sci 2016;8:84-9.
30. Mohammad A, Al-Sayah. Analytical strategies for genotoxic impurities in the pharmaceutical industry. In American Pharmaceutical Review; 2014.
31. Derek I Robinson. Control of genotoxic impurities in active pharmaceutical ingredients: a review and perspective. Org Process Res Dev 2010;14:946–59.
Statistics
38 Views | 33 Downloads
Citations
How to Cite
N., S. J., & MUVVALA, V. (2021). A SELECTIVE AND SENSITIVE LC-MS/MS METHOD FOR QUANTIFICATION OF FOUR POTENTIAL GENOTOXIC IMPURITIES IN ATAZANAVIR SULFATE DRUG SUBSTANCE IN TRACE LEVEL. International Journal of Applied Pharmaceutics, 13(3), 137-144. https://doi.org/10.22159/ijap.2021v13i3.40911
Section
Original Article(s)